Published in Healthcare Mergers, Acquisitions and Ventures Week, January 14th, 2006
According to recent research from Germany, "RA has proven to possess modest but distinct activity in metastatic RCC, at least in a subgroup of patients. However, the exact molecular mechanisms leading to success or failure of RA application in individual patients are still unknown."
"As earlier studies have indicated that in RCC the RAR beta might play a central role in RA signaling, we investigated the expression of the isoforms RAR-beta(1+2) in primary conventional and chromophobe RCC. We used quantitative RT-PCR methodology to study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.